Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 11, 2008

Presidio Pharmaceuticals to Use Numerate’s Drug Engineering Platform to Advance Hepatitis C Therapeutics

  • Presidio Pharmaceuticals, a specialty pharmaceutical company focused on developing and commercializing small molecule compounds for the treatment of HIV-1 and hepatitis C virus (HCV), and Numerate entered into a research collaboration to discover and develop small molecule inhibitors of HCV.

    “Numerate has a promising computational approach that we believe will help expand our HCV portfolio in a highly competitive area encumbered by many patents,” says Richard Colonno, CSO of Presidio. “Numerate’s drug-engineering process addresses the key design criteria in parallel with a focus on delivering advanced lead compounds quickly. The process accelerates the discovery and design of novel leads and reduces the time and cost needed to advance compounds into clinical trials.”

    Numerate has developed and extensively validated a drug-engineering platform that rapidly and cost-effectively delivers small molecule therapeutics optimized for efficacy, safety, and patentability, according to Guido Lanza, CEO. Numerate applies this technology to design and develop small molecule drugs in collaboration with a variety of partners and in the advancement of therapeutic programs including a multitargeted therapy for type II diabetes and cardiovascular disease.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »